Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – 9,10-seco- cyclopentanohydrophenanthrene ring system doai
Patent
1992-10-13
1993-09-21
Waddell, Frederick E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
9,10-seco- cyclopentanohydrophenanthrene ring system doai
514 63, A61K 3159, A61K 31695
Patent
active
052469255
ABSTRACT:
This invention provides a novel class of vitamin D-related compounds, namely the 1.alpha.-hydroxy-19-nor-vitamin D analogs, as well as a general method for their chemical synthesis. The compounds exhibit pronounced activity in arresting the proliferation of undifferentiated cells, including malignant cells, and in inducing their differentiation, and thus represent novel therapeutic agents for the treatment of malignant and other diseases characterized by the proliferative growth of undifferentiated cells. Formulations for therapeutic use and treatment methods are also provided.
REFERENCES:
patent: 4769181 (1988-09-01), DeLuca et al.
Chemical Abstracts (110:19004r) 1989.
DeLuca Hector F.
Perlman Kato L.
Prahl Jean M.
Schnoes Heinrich K.
Sicinski Rafal R.
Waddell Frederick E.
Weddington K.
Wisconsin Alumni Research Foundation
LandOfFree
19-nor-vitamin D compounds for use in treating hyperparathyroidi does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 19-nor-vitamin D compounds for use in treating hyperparathyroidi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 19-nor-vitamin D compounds for use in treating hyperparathyroidi will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1049885